Cytokinetics, Inc. has announced its Vision 2025, outlining key imperatives for the next five years, including achieving regulatory approvals for at least two drugs, building commercial capabilities, and expanding its development pipeline. The company also detailed its expected 2020 milestones, focusing on advancing cardiac and skeletal muscle programs, with significant clinical trial results anticipated.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.